Cancer-fighting MedTech CellCentric has raised £90m in fresh funding. The Series C round will support the advancement of the Cambridge company’s oral treatment for multiple myeloma, inobrodib. The financing was co-led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital, as well as BrightEdge, the American Cancer Society’s venture capital … Continue reading CellCentric raises £90m to prevent cancer deaths